22 май 2018 г. - FDA convened a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for buprenorphine sublingual spray, submitted by INSYS Development Company, Inc., for the treatment of moderate-to-severe acute pain where the use of an opioid analgesic isappropriate.
Добавлено на ленту времени:
Дата:
22 май 2018 г.
Сейчас
~ 7 гг и 5 мес назад